Cordis Corporation
WATERLOO, Belgium, September 30, 2010 - Investigators reported results of SORT-OUT IV, comparing Cordis
Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE
V (R) Everolimus-eluting Stent in the primary endpoint of MACE (major acute
coronary events) at nine months.
STOCKHOLM, September 2, 2010 - Three new analyses of subgroups from the SORT OUT III study
presented at the European Society of Cardiology (ESC) meeting in Stockholm,
Sweden, provide additional detail on longer-term follow-up subgroup safety
and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups
(diabetes, acute coronary syndrome and multiple lesion).
STOCKHOLM, August 31, 2010 - Cordis Corporation, a worldwide leader in the development and manufacture
of interventional vascular technology, announced today at European Society of
Cardiology in Stockholm that the results of follow-up tests undertaken ten
years after the first patient was treated with a CYPHER(R) Sirolimus-eluting
coronary stent have proven outstanding long-term efficacy and safety and were
published earlier this year in "JACC: Cardiovascular Interventions".
PARIS, May 27, 2010 - Cordis Corporation, a worldwide leader in the development and manufacture
of interventional vascular technology, announced the launch of the
ExoSeal(TM) Vascular Closure Device.
PARIS, May 25, 2010 - At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued
to demonstrate excellent safety and efficacy outcomes compared to Taxus(R)
Liberte(R) according to new data presented today from the NEVO(TM) RES-I
clinical trial.
More News
- Trial Will Explore a More Individualized Endovascular Approach Targeting a Broader Patient Population for a Life-Threatening Condition that Affects 27 Million People Worldwide
- Christian M. Spaulding, M.D., Ph.D. to Join Cordis Corporation
- SORT OUT III Data Presented at American College of Cardiology Meeting in Atlanta and Published in the Lancet
- PRESILLION(TM) PLUS CoCr Coronary Stent Offers New Levels of Delivery, Support and Restoration for Arteriosclerotic Arteries
- NEVO(TM) Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus(R) Liberte(R) Stent in Pivotal Clinical Trial